BCRX:NSD-BioCryst Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.21

Change

0.00 (0.00)%

Market Cap

USD 1.63B

Volume

9.07M

Average Target Price

USD 9.75 (+5.86%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703

Company Website : http://www.biocryst.com

Address : 4505 Emperor Boulevard, Durham, NC, United States, 27703

Employees : 140

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 3.03

52 Week High : 9.78

Short Ratio : 2.95

52 Week Low : 1.58

Shorted Shares : 30,945,985

200 Day Moving Average : 5.07

Shorted Shares Previous Month : 37,040,634

50 Day Moving Average : 7.98

Shares Held By Insiders : 8.52%

Short Percentage : 18.00%

Shares Held by Institutions : 73.95%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD57.38B 19.71 15.20
MRNA Moderna, Inc

N/A

 USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

N/A

 USD34.10B N/A N/A
SGEN Seagen Inc

N/A

 USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

N/A

 USD31.99B 22.60 11.74
GMAB Genmab A/S

N/A

 USD28.33B 26.59 3.19
BNTX BioNTech SE

N/A

 USD26.11B -99,999.99 N/A
INCY Incyte Corporation

N/A

 USD21.44B 47.64 35.20

ETFs Containing BCRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.62% 68% D+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.62% 68% D+ 82% B-
Trailing 12 Months  
Capital Gain 227.76% 92% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 227.76% 92% A- 93% A
Trailing 5 Years  
Capital Gain 26.34% 56% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.34% 56% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 23.34% 63% D 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.34% 63% D 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 71.70% 36% F 16% F
Risk Adjusted Return 32.55% 63% D 58% F
Market Capitalization 1.63B 78% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 48.34 3% F 3% F
Price / Cash Flow Ratio -18.15 70% C- 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -87.85% 30% F 11% F
Return on Assets -57.39% 12% F 4% F
Debt to Equity Ratio 107.94% 15% F 21% F
Technical Ratios  
Short Ratio 2.95 51% F 45% F
Short Percent 18.84% 9% F 10% F
Beta 3.03 4% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.